Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol
Helen M. Colhoun, Lawrence A. Leiter, Dirk Müller‐Wieland, et al.
Cardiovascular Diabetology (2020) Vol. 19, Iss. 1
Open Access | Times Cited: 25

Showing 25 citing articles:

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes
Nikolaus Marx, Massimo Federici, Katharina Schütt, et al.
European Heart Journal (2023) Vol. 44, Iss. 39, pp. 4043-4140
Open Access | Times Cited: 698
Apolipoprotein B and Cardiovascular Disease: Biomarker and Potential Therapeutic Target
Jennifer Behbodikhah, Saba Ahmed, Ailin Elyasi, et al.
Metabolites (2021) Vol. 11, Iss. 10, pp. 690-690
Open Access | Times Cited: 184
Lipoprotein(a): Knowns, unknowns and uncertainties
Massimiliano Ruscica, Cesare R. Sirtori, Alberto Corsini, et al.
Pharmacological Research (2021) Vol. 173, pp. 105812-105812
Closed Access | Times Cited: 69
Personalized management of dyslipidemias in patients with diabetes—it is time for a new approach (2022)
Maciej Banach, Stanisław Surma, Željko Reiner, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 66
High triglyceride-glucose index is associated with early recurrent ischemic lesion in acute ischemic stroke
Ki‐Woong Nam, Hyung‐Min Kwon, Yong-Seok Lee
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 41
Role of lipoprotein(a) in atherosclerotic cardiovascular disease: A review of current and emerging therapies
Ibrahim S. Alhomoud, Azita H. Talasaz, Anurag Mehta, et al.
Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy (2023) Vol. 43, Iss. 10, pp. 1051-1063
Open Access | Times Cited: 16
Research progress on alternative non-classical mechanisms of PCSK9 in atherosclerosis in patients with and without diabetes
Ying Tang, Shenglan Li, Jiahui Hu, et al.
Cardiovascular Diabetology (2020) Vol. 19, Iss. 1
Open Access | Times Cited: 36
Cholesterol lowering therapies and achievement of targets for primary and secondary cardiovascular prevention in type 2 diabetes: unmet needs in a large population of outpatients at specialist clinics
Mario Luca Morieri, Angelo Avogaro, Gian Paolo Fadini
Cardiovascular Diabetology (2020) Vol. 19, Iss. 1
Open Access | Times Cited: 33
LDL cholesterol levels and in-hospital bleeding in patients on high-intensity antithrombotic therapy: findings from the CCC-ACS project
Qing Yang, Dongdong Sun, Chongzhe Pei, et al.
European Heart Journal (2021) Vol. 42, Iss. 33, pp. 3175-3186
Open Access | Times Cited: 25
Association of circulating proprotein convertase subtilisin/kexin type 9 levels and the risk of incident type 2 diabetes in subjects with prediabetes: a population-based cohort study
Jie Shi, Weiwei Zhang, Yixin Niu, et al.
Cardiovascular Diabetology (2020) Vol. 19, Iss. 1
Open Access | Times Cited: 20
Targeting NPC1 in Renal Cell Carcinoma
Rushaniya Fazliyeva, Peter Makhov, Robert G. Uzzo, et al.
Cancers (2024) Vol. 16, Iss. 3, pp. 517-517
Open Access | Times Cited: 2
Classical and Novel Lipid-Lowering Therapies for Diabetic Patients with Established Coronary Artery Disease or High Risk of Coronary Artery Disease—A Narrative Clinical Review
Nikolaos Velidakis, Panagiotis Stachteas, Evangelia Gkougkoudi, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 5, pp. 568-568
Open Access | Times Cited: 2
Long-term prognostic utility of low-density lipoprotein (LDL) triglyceride in real-world patients with coronary artery disease and diabetes or prediabetes
Jing‐Lu Jin, Huiwen Zhang, Ye‐Xuan Cao, et al.
Cardiovascular Diabetology (2020) Vol. 19, Iss. 1
Open Access | Times Cited: 15
Potential biomarker in serum for predicting susceptibility to type 2 diabetes mellitus: Free fatty acid 22:6
Yinghua Ma, Jianyu Xiong, Xueting Zhang, et al.
Journal of Diabetes Investigation (2020) Vol. 12, Iss. 6, pp. 950-962
Open Access | Times Cited: 15
Unravelling lipoprotein metabolism with stable isotopes: tracing the flow
Qidi Ying, Dick C. Chan, P. Hugh R. Barrett, et al.
Metabolism (2021) Vol. 124, pp. 154887-154887
Closed Access | Times Cited: 14
Morphologies and composition changes in nonculprit subclinical atherosclerosis in diabetic versus nondiabetic patients with acute coronary syndrome who underwent long-term statin therapy
Pei-na Meng, Jia-cong Nong, Yi Xu, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 5
Feeding-induced hepatokines and crosstalk with multi-organ: A novel therapeutic target for Type 2 diabetes
Rongbin Chen, Qiyu Wang, Yuan Yuan Wang, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 4
Impact of Alirocumab on Release Markers of Atherosclerotic Plaque Vulnerability in Patients with Mixed Hyperlipidemia and Vulnerable Atherosclerotic Plaque
Michał Kosowski, Marcin Basiak, Marcin Hachuła, et al.
Medicina (2022) Vol. 58, Iss. 7, pp. 969-969
Open Access | Times Cited: 7
PCSK9 inhibitor effectively attenuates cardiometabolic impairment in obese-insulin resistant rats
Patchareeya Amput, Siripong Palee, Busarin Arunsak, et al.
European Journal of Pharmacology (2020) Vol. 883, pp. 173347-173347
Closed Access | Times Cited: 5
Effects of intracranial atherosclerosis and atrial fibrillation on the prognosis of ischemic stroke with active cancer
Ki‐Woong Nam, Hyung‐Min Kwon, Yong-Seok Lee
PLoS ONE (2021) Vol. 16, Iss. 11, pp. e0259627-e0259627
Open Access | Times Cited: 4
PCSK9 inhibitors: role in reducing cardiovascular diseases
O. V. Malyarevskaya, А. М. Намитоков, С. В. Кручинова, et al.
South Russian Journal of Therapeutic Practice (2022) Vol. 3, Iss. 2, pp. 32-40
Open Access | Times Cited: 3
Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease risk: current status and treatments
Gissette Reyes‐Soffer
Current Opinion in Endocrinology Diabetes and Obesity (2021) Vol. 28, Iss. 2, pp. 85-89
Closed Access | Times Cited: 3
Relation Between New York Heart Association Functional Class and Remnant Cholesterol, and Non-high Density Lipoprotein Cholesterol in Coronary Heart Disease Patients With Type 2 Diabetes Mellitus
Qi Cheng, Zhu Li, Xu Wang, et al.
Angiology (2022) Vol. 74, Iss. 1, pp. 39-46
Closed Access | Times Cited: 1
Advanced progress of the relationship between PCSK9 monoclonal antibodies and hyperglycemic adverse events
Ruixing Zhang, Yongxiang Wang, Peng Yu, et al.
Frontiers in Cardiovascular Medicine (2023) Vol. 10
Open Access
Feasibility and efficacy of PCSK9 inhibitors in cases of statin therapy limitation or intolerance
К. О. Shnaider, V. A. Baranova, М. Л. Максимов
Glavvrač (Chief Medical Officer) (2023), Iss. 7, pp. 22-33
Closed Access
Page 1

Scroll to top